RNA Therapeutics Are Stepping Out of the Maze

被引：7
作者：
Agrawal, Sudhir [1 ,2 ]
机构：
[1] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA
[2] Arnay Sci LLC, Shrewsbury, MA 01545 USA
来源：
TRENDS IN MOLECULAR MEDICINE | 2020年 / 26卷 / 12期
关键词：
ANTISENSE;
D O I：
10.1016/j.molmed.2020.08.007
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
RNA therapeutics are finally taking their place as a main drug category alongside small molecules and proteins. Here, we follow the twists and turns on their road to success and highlight areas of ongoing research.
引用
收藏
页码：1061 / 1064
页数：4
相关论文
共 17 条
  • [1] Antisense and siRNA as agonists of Toll-like receptors
    Agrawal, S
    Kandimalla, ER
    [J]. NATURE BIOTECHNOLOGY, 2004, 22 (12) : 1533 - 1537
  • [2] OLIGODEOXYNUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHOROTHIOATES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS
    AGRAWAL, S
    GOODCHILD, J
    CIVEIRA, MP
    THORNTON, AH
    SARIN, PS
    ZAMECNIK, PC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (19) : 7079 - 7083
  • [3] Agrawal S., 2019, Advances in Nucleic Acid Therapeutics
  • [4] CRICK F H, 1958, Symp Soc Exp Biol, V12, P138
  • [5] Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
    Finkel, R. S.
    Mercuri, E.
    Darras, B. T.
    Connolly, A. M.
    Kuntz, N. L.
    Kirschner, J.
    Chiriboga, C. A.
    Saito, K.
    Servais, L.
    Tizzano, E.
    Topaloglu, H.
    Tulinius, M.
    Montes, J.
    Glanzman, A. M.
    Bishop, K.
    Zhong, Z. J.
    Gheuens, S.
    Bennett, C. F.
    Schneider, E.
    Farwell, W.
    De Vivo, D. C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (18) : 1723 - 1732
  • [6] COMPLEMENT ACTIVATION AND HEMODYNAMIC-CHANGES FOLLOWING INTRAVENOUS ADMINISTRATION OF PHOSPHOROTHIOATE OLIGONUCLEOTIDES IN THE MONKEY
    GALBRAITH, WM
    HOBSON, WC
    GICLAS, PC
    SCHECHTER, PJ
    AGRAWAL, S
    [J]. ANTISENSE RESEARCH AND DEVELOPMENT, 1994, 4 (03): : 201 - 206
  • [7] Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
    Kim, J.
    Hu, C.
    El Achkar, C. Moufawad
    Black, L. E.
    Douville, J.
    Larson, A.
    Pendergast, M. K.
    Goldkind, S. F.
    Lee, E. A.
    Kuniholm, A.
    Soucy, A.
    Vaze, J.
    Belur, N. R.
    Fredriksen, K.
    Stojkovska, I.
    Tsytsykova, A.
    Armant, M.
    DiDonato, R. L.
    Choi, J.
    Cornelissen, L.
    Pereira, L. M.
    Augustine, E. F.
    Genetti, C. A.
    Dies, K.
    Barton, B.
    Williams, L.
    Goodlett, B. D.
    Riley, B. L.
    Pasternak, A.
    Berry, E. R.
    Pflock, K. A.
    Chu, S.
    Reed, C.
    Tyndall, K.
    Agrawal, P. B.
    Beggs, A. H.
    Grant, P. E.
    Urion, D. K.
    Snyder, R. O.
    Waisbren, S. E.
    Poduri, A.
    Park, P. J.
    Patterson, A.
    Biffi, A.
    Mazzulli, J. R.
    Bodamer, O.
    Berde, C. B.
    Yu, T. W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (17) : 1644 - 1652
  • [8] Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
    Lim, Kian Huat
    Han, Zhou
    Jeon, Hyun Yong
    Kach, Jacob
    Jing, Enxuan
    Weyn-Vanhentenryck, Sebastien
    Downs, Mikaela
    Corrionero, Anna
    Oh, Raymond
    Scharner, Juergen
    Venkatesh, Aditya
    Ji, Sophina
    Liau, Gene
    Ticho, Barry
    Nash, Huw
    Aznarez, Isabel
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
  • [9] Metelev V., Patent No. [US6346614, 6346614]
  • [10] Metelev V., Patent No. [US5652355, 5652355]
12